Abstract
Multiple Sclerosis (MS) is a chronic inflammatory disease of the CNS which is characterized by large mononuclear cell infiltration and significant demyelination. CXCL8 is a chemo-attractant for both neutrophils and monocytes and triggers their firm adhesion to endothelium. In this study, we demonstrate that serum CXCL8 and CXCL8 secretion from PBMCs are significantly higher in untreated MS patients compared to controls and are significantly reduced in MS patients receiving interferon-beta1a therapy. We suggest that CXCL8 may serve as a marker of monocyte activity in MS and may play a role in monocyte recruitment to the CNS.
Copyright 2004 Elsevier B.V.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Biomarkers / blood
-
Central Nervous System / immunology
-
Central Nervous System / physiopathology
-
Chemokines, CXC / blood*
-
Chemokines, CXC / immunology*
-
Chemokines, CXC / metabolism
-
Chemotaxis, Leukocyte / drug effects
-
Chemotaxis, Leukocyte / immunology*
-
Female
-
Humans
-
Intercellular Signaling Peptides and Proteins / blood*
-
Intercellular Signaling Peptides and Proteins / immunology*
-
Intercellular Signaling Peptides and Proteins / metabolism
-
Interferon beta-1a
-
Interferon-beta / pharmacology
-
Interferon-beta / therapeutic use
-
Male
-
Middle Aged
-
Monocytes / drug effects
-
Monocytes / immunology*
-
Multiple Sclerosis / blood*
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / immunology*
-
Neutrophils / drug effects
-
Neutrophils / immunology
-
Predictive Value of Tests
-
Up-Regulation / drug effects
-
Up-Regulation / immunology
Substances
-
Biomarkers
-
Chemokines, CXC
-
Intercellular Signaling Peptides and Proteins
-
Interferon-beta
-
Interferon beta-1a